Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics deal stands out

A lit­tle over 3 years ago, Mer­ck splashed in­to a li­cens­ing deal with As­traZeneca cov­er­ing their block­buster Lyn­parza fran­chise with $1.6 bil­lion in cash up­front …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER